Abstract: The present invention relates to topical ophthalmic composition of Apremilast. The said ophthalmic composition has been designed for better penetration and reach to the target site for ophthalmic applications, thereby giving a better efficacious formulation. The present invention also relates to method of relieving the symptoms of dry eye by enhancing the tear secretion, reducing inflammation and moisturising the surface of eye thereby reducing the friction or irritation, as is generally caused due to various dry eye disorders. The presently proposed compositions are also proposed to be useful as delivery vehicles for ophthalmic drugs, and as wetting or lubrication substitute for the contact lens.

Abstract: The present invention is related to methods of treating, preventing, correcting and / or managing non-psoriatic skin diseases or disorders, characterized by dry, hardened, scaly or flaky skin and fissures. The present invention also provides various topical administration of therapeutically or prophylactically effective amount of an Apremilast for treating, preventing, correcting and/ or managing non-psoriatic skin diseases or disorders, characterized by dry, hardened, scaly or flaky skin and fissures. The present invention further relates to a method of treating, preventing, and managing the conditions that cause cytokine storm, by administration of Apremilast.

Abstract: The present invention provides a low dose topical composition of Apremilast with pharmaceutically acceptable excipients. The present invention also relates to a topical clear gel composition of apremilast for delivering a desired therapeutic amount of drug to the site of action after topical application. The present invention also provides a process for preparation process for preparation of low dose apremilast topical composition with enhanced diffusion and dose-proportionate linear drug release from the composition.

Abstract: The present invention provides a topical composition of Apremilast with lipohilic agents. The plurality of excipients each present in amounts, and in combination, to effectively control the release of Apremilast from the composition for better penetration in to the skin. The present invention also provides a process for preparation of the apremilast topical composition with enhanced skin penetration and efficacy. The present invention also relates to a method of treating psoriasis and other related skin condition using a lipophilic topical composition of Apremilast, wherein the permeation of Apremilast through the skin is significantly enhanced with the use of lipophilic components in the composition.

Abstract: The present invention relates to a novel topical pharmaceutical composition of Teriflunomide, comprising teriflunomide or its pharmaceutically acceptable salt in combination with pharmaceutically acceptable excipients, wherein the said composition is effective for use in treatment of pain associated with disorders like inflammation and arthritis. The composition is also useful for relieving the symptoms of pain and arthritis in subjects suffering from autoimmune diseases like multiple sclerosis or rheumatoid arthritis. The said topical composition of teriflunomide is prepared in the form of topical gel, topical cream, topical ointment, topical solution, lotion or topical spray with significantly enhanced permeability and diffusion rate of the drug.

Abstract: A topical pharmaceutical composition of apremilast used for the treatment of psoriasis and/or psoriatic arthritis is provided. It further relates to processes of preparation of the compositions and the method of use for these compositions.

Abstract: The present invention relates to topical pharmaceutical compositions of apremilast used for the treatment of psoriasis and/or psoriatic arthritis. It further relates to processes of preparation of the compositions and the method of use for these compositions.

Abstract: The present invention relates to pharmaceutical compositions of Eliglustat. In particular the present invention relates to stable amorphous Eliglustat premix having enhanced stability and dissolution properties. The present invention also provide a stable premix composition comprising amorphous Eliglustat or a pharmaceutical acceptable salt thereof, pharmaceutical compositions comprising the premixes, and processes for preparing the same. The compositions prepared in the present invention includes sublingual or mouth dissolving tablets, and capsules of Eliglustat and/or its pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable carrier.

Abstract: The present invention relates to topical compositions comprising apremilast. It also relates to processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatosis, eczema, rosacea, acne vulgaris, allergies, contact and atopic dermatitis, pruritus, seborrhea, skin cancers, inflammation and other associated skin conditions.

Abstract: The present invention relates to topical pharmaceutical compositions of apremilast used for the treatment of psoriasis and/or psoriatic arthritis. It further relates to processes of preparation of the compositions and the method of use for these compositions.

Abstract: Premixes of dexlansoprazole with pharmaceutical excipients, processes for preparing premixes, pharmaceutical formulations containing the premixes, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.

Abstract: Pharmaceutical formulations comprising desvenlafaxine, processes for preparing formulations comprising desvenlafaxine, and therapeutic uses and methods of treatment employing formulations comprising desvenlafaxine.

Abstract: Compositions containing atorvastatin, including its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs and their mixtures, and processes for preparing the same. Further aspects relate to pharmaceutical formulations comprising compositions containing atorvastatin, or a salt thereof, processes for preparing the same, and their methods of use, treatment and administration.

Abstract: Solubility-enhanced forms of aprepitant and processes for preparing such forms. The invention also provides solubility-enhanced forms of aprepitant that also possess stability against solid state conversions. Certain solubility-enhanced forms of aprepitant comprise a cyclodextrin or any of its derivatives. Other solubility-enhanced forms of aprepitant comprise fine particle preparations of aprepitant. The invention further provides non-nanoparticulate pharmaceutical formulations prepared using solubility-enhanced forms of aprepitant. The invention also provides taste-masked and orally disintegrating pharmaceutical formulations comprising aprepitant. Further, pharmaceutical formulations comprising solubilityenhanced forms of aprepitant and processes of preparation of such formulations, as well as methods of using them are provided.

Abstract: Compositions and/or formulations comprising solifenacin or a salt thereof and processes for preparing the same. Certain compositions and formulations contain a stable amorphous form of solifenacin succinate.

Abstract: Premixes of dexlansoprazole with pharmaceutical excipients, processes for preparing premixes, pharmaceutical formulations containing the premixes, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.

Abstract: Dosage forms for administering a triptan and a nonsteroidal anti-inflammatory drug are disclosed, including multilayered tablets and mini-tablets. These multilayered tablets can be in a side-by-side arrangement, can be inlayed, or one layer can completely surround another. These can be administered in a capsule or directly. Other formulations are also disclosed.

Abstract: A solid pharmaceutical dosage form comprises a substrate containing an active agent and a solid composition deposited onto areas of a surface of the substrate and containing an active agent.